Study_Mentioned
stringlengths 3
205
⌀ | Product_Mentioned
stringlengths 3
429
⌀ | Company_Mentioned
stringlengths 3
288
| Indication_Mentioned
stringlengths 2
111
| Non_Social
int64 1
1
| Tag
stringlengths 2
1.13k
⌀ | Adjusted_Date
stringlengths 11
16
| Conversation_Id
float64 422,000,000B
1,680,000,000B
| Clean_Tweet
stringlengths 1
298
⌀ | Profile_Bio
stringlengths 1
185
⌀ | Class
stringclasses 6
values | User_Type
stringclasses 17
values |
|---|---|---|---|---|---|---|---|---|---|---|---|
epcore nhl-2 | epcoritamab | abbvie,genmab | lymphoma | 1 | ['lymsm', 'dlbcl'] | 6/3/2022 16:06 | 1,530,000,000,000,000,000 | too early to make a call on sc epco #rchop in dlbcl #lymsm but seems a safe option #asco22 | A hematologist @MoffittNews with interest in #lymsm. Tweets are not endorsements, and not medical advice. | Individual | HCP |
ARC-101 Arm1 | CART-ddBCMA,ARC-T,Anti-BCMA SparX | arcellx | multiple myeloma | 1 | ['multiplemyeloma', 'mmsm', 'cart,(-cartitude)'] | 6/5/2022 11:05 | 1,530,000,000,000,000,000 | . of presented results during #asco22 from a phase 1 study that found cart-ddbcma induces promising responses in relapsed/refractory #multiplemyeloma. #ascodailynews #hemonc #mmsm | Account of the American Society of Clinical Oncology & its affiliate the Association for Clinical Oncology. Assoc tweets labeled #ASCOAdvocacy. RTs ? endorse. | Company / Organization | Professional |
ARC-101 Arm1 | CART-ddBCMA | arcellx | multiple myeloma | 1 | ['multiple myeloma', 'cart,(-cartitude)', 'arcellx'] | 6/3/2022 17:24 | 1,530,000,000,000,000,000 | today, arcellx announced continued robust long-term responses from its cart-ddbcma phase 1 expansion trial in patients with relapsed or refractory multiple myeloma at the 2022 annual meeting. read the full press release: #arcellx
#asco22 | We are a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies. | Company / Organization | Pharma / Biotech |
ARC-101 Arm1 | CART-ddBCMA | arcellx | multiple myeloma | 1 | ['mmsm', 'car t'] | 6/5/2022 9:02 | 1,530,000,000,000,000,000 | exciting results from of ddbcma car t for r/r myeloma, with 69% of those with 12/12 followup maintaining a cr for a year or more - will be cool to see longer followup #mmsm #tcellrx #asco22 | haematology registrar | evidence-based medicine | MPH @Harvard | health policy @PORTAL_research | physiology | musician | writer | @_futurethinkers cofounder | Individual | Research / Science |
Not Tagged | Not Tagged | astellas,eli lilly,abbvie,daiichi sankyo | Not Tagged | 1 | [' vision', 'thank you', 'astellasus', 'daiichisankyous', 'astellas', 'daiichi', 'abbvie', 'lillypad'] | 6/6/2022 9:00 | 1,530,000,000,000,000,000 | thank you, , , , , and , for supporting our mission as #asco22 track donors at the visionary level! we appreciate your generosity and vision! | @ASCO's foundation funding research to conquer every cancer, for every patient, everywhere. | Company / Organization | Advocacy / Charity |
EV-103 | enfortumab vedotin | astellas,seagen | gu | 1 | ['bladder', 'enfortumab'] | 6/4/2022 11:53 | 1,530,000,000,000,000,000 | . will present 1:15pmcst today at #asco22 on antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients w/muscle-invasive bladder cancer who are cisplatin-ineligible. | Yale Cancer Center is a collaboration between renowned cancer researchers and physicians @Yale and @SmilowCancer. | Company / Organization | Hospital / Clinic |
ev-301 | enfortumab vedotin | astellas,seagen | gu | 1 | ['bladder'] | 6/4/2022 17:41 | 1,530,000,000,000,000,000 | #asco22 outstanding discussion by on strategy in neoadjuvant rx and drug development in #bladdercancer : i have failed over and over again in my life, and that s why i succeed. | Medical Oncologist. Editor-in-chief: @ASCO Daily News; Presidential Endowed Chair, @HuntsmanCancer (NCI-CCC) @UUtah, FCOI https://t.co/qcdl195o3E | Individual | HCP |
ev-301 | enfortumab vedotin | astellas,seagen | gu | 1 | ['bladder'] | 6/4/2022 17:45 | 1,530,000,000,000,000,000 | important considerations from discussion by on neoadjuvant therapy in #bladdercancer #asco22 | Oncólogo médico en @parctauli y Hospital de Barcelona. Vocal de la Junta Directiva de @sogug1. Wine lover. Life-enjoying! | Individual | HCP |
CM-214 | ipilimumab,nivolumab | bms | gu | 1 | ['import'] | 6/3/2022 16:04 | 1,530,000,000,000,000,000 | it depends which toxicity we are talking about. in general hypertension is one of the most important as prognostic for good responder. but it usually does not impact negatively qol #asco22 | Scientific Committee Member LACOG - GU. Medical Oncologist at Hospital Albert Einstein and CPO. Owner and founder BIO. Following or RT does not mean endorsement | Individual | HCP |
PILOT | Lisocabtagene Maraleucel | BMS | lymphoma | 1 | ['lymsm', 'dlbcl', 'cart,(-cartitude)'] | 6/3/2022 15:56 | 1,530,000,000,000,000,000 | lisocel #cart setting the benchmark for what to expect from second line therapy for non transplant eligible patients with dlbcl #lymsm with cr 54% and no grade 4/5 crs or neurotoxicity #asco22 | A hematologist @MoffittNews with interest in #lymsm. Tweets are not endorsements, and not medical advice. | Individual | HCP |
cm-9er | nivolumab,apexigen | bms,exelixis | gu | 1 | ['nivo', 'rcc,(-irccs),(-srcc),(-urcc)'] | 6/3/2022 15:09 | 1,530,000,000,000,000,000 | depth of response was associated with survival outcomes in pts with mrcc treated with nivo+cabo #asco22 | Medical Oncologist/T?bbi Onkolog
#genitourinary and #gastrointestinal cancers
#computational oncology
Tweets for scientific purposes. Not medical advice! | Individual | HCP |
cm-9er | nivolumab,cabozantinib | bms,exelixis | gu | 1 | ['nivo', 'renal,(-adrenal)', 'nivolumab', 'cabozantinib'] | 6/4/2022 6:46 | 1,530,000,000,000,000,000 | nivolumab/cabozantinib associated with greater proportion of deep objective responses for advanced renal cell carcinoma #asco22 | Chief MedOnc @SylvesterCancer. Helping improve Cancer Control in LMICs. Editor-in-Chief @JCOGO_ASCO, Board Member @UICC - co-chair #ATOMcoalition | Individual | HCP |
COSMIC-303 | nivolumab,cabozantinib,ipilimumab | bms,exelixis | Not Tagged | 1 | ['nivo', 'cabozantinib', ' ipi '] | 6/4/2022 14:22 | 1,530,000,000,000,000,000 | ain t there a ipi nivo cabozantinib trial going on ? | Doing my part to help onc patients. + fintwit | Individual | HCP |
CM-274,AMBASSADOR,Imvigor-010 | nivolumab,pembrolizumab,atezolizumab | bms,merck,roche | gu,thoracic,lymphoma | 1 | ['urothelial carcinoma', 'nivo', 'import', 'urothelial'] | 6/3/2022 13:32 | 1,530,000,000,000,000,000 | dr. discusses the adjuvant immunotherapies in urothelial carcinoma and highlights the ongoing trials. important to point out that adjuvant nivo should only be considered if persistent disease after neoadjuvant gem-cis or cis-ineligible patient. #asco22 | Medical oncologist at @BPorgbr. Former fellow of GU oncology @DanaFarber @Harvard @MOCbrasil. #GUcancer | Individual | HCP |
CM-274,AMBASSADOR,Imvigor-010 | nivolumab,pembrolizumab,atezolizumab | bms,merck,roche | gu,thoracic,lymphoma | 1 | ['urothelial'] | 6/3/2022 13:29 | 1,530,000,000,000,000,000 | brilliant presentation about adjuvant therapy in kidney and urothelial cancer by . controversial topic, and more to come in the future. #asco22 | Medical Oncologist - Urologic Oncology. Hospital Universitario La Paz - IdiPAZ, Madrid | Individual | HCP |
COSMIC-021,everest,lung-map,cm-9er,krystal-1 | ramucirumab,pembrolizumab,cabozantinib,atezolizumab,nivolumab,everolimus,Adagrasib | eli lilly,merck,exelixis,bms,mirati,roche | gu,thoracic,other | 1 | ['everest', 'lung', 'cosmic-021', 's1800a', 'bladder'] | 6/4/2022 8:03 | 1,530,000,000,000,000,000 | a pleasure to bring you day1 of #asco22 through our daily round up covering;
everest checkmate9 er cosmic-021 s1800a krystal01 #kidneycancer #bladdercancer #lungcancer | Clinical Oncologist from Texas????Director of @OncoAlert ?? Proudly NIH, NCI & MDA trained. An ounce of prevention equals a pound of cure. Views are own?? | Individual | Media / News |
atlantis | cabozantinib | exelixis | gu | 1 | ['improve', 'muc ,(-much)'] | 6/3/2022 16:14 | 1,530,000,000,000,000,000 | maintenance w/ cabo after chemo in muc did not improved pfs and os. #asco22 | Medical Oncologist/T?bbi Onkolog
#genitourinary and #gastrointestinal cancers
#computational oncology
Tweets for scientific purposes. Not medical advice! | Individual | HCP |
atlantis | cabozantinib | exelixis | gu | 1 | ['urothelial carcinoma', 'cabozantinib', 'bladder', 'urothelial'] | 6/4/2022 7:08 | 1,530,000,000,000,000,000 | significant benefit not seen with maintenance cabozantinib in advanced urothelial carcinoma #asco22 #urology #urologist #urothelialcarcinoma #bladdercancer | Expert clinical analysis. Practice advice. Policy perspectives. | Company / Organization | Publication / Journal |
atlantis | cabozantinib | exelixis | gu | 1 | ['blcsm', 'cabozantinib', 'urothelial'] | 6/4/2022 7:51 | 1,530,000,000,000,000,000 | single-agent cabozantinib stalls as maintenance therapy in advanced urothelial cancer #asco22 #blcsm #oncology | Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management. | Company / Organization | Publication / Journal |
atlantis | cabozantinib | exelixis | gu | 1 | ['cabometyx', 'bladder'] | 6/5/2022 11:30 | 1,530,000,000,000,000,000 | despite its favorable safety profile, cabometyx was not superior to placebo when it was added after chemo to treat bladder cancer. future trials should consider combining novel agents with maintenance immunotherapy, a researcher said at #asco22 | Cancer updates, research and education for patients with cancer, survivors and their caregivers to become empowered advocates in their journey. | Company / Organization | Advocacy / Charity |
atlantis | cabozantinib | exelixis | gu | 1 | ['urothelial carcinoma', 'urothelial', 'cabozantinib', 'blcsm'] | 6/5/2022 18:00 | 1,530,000,000,000,000,000 | in a phase 2 clinical trial, the use of maintenance #cabozantinib following chemotherapy in patients with advanced urothelial carcinoma demonstrated tolerability but did not show a significant benefit vs placebo. #uc #blcsm #asco22 | Oncology news and insights from leading researchers and cancer centers. | Bot / Aggregator | Media / News |
atlantis | cabozantinib | exelixis | gu | 1 | ['bladder', 'cabozantinib'] | 6/3/2022 18:53 | 1,530,000,000,000,000,000 | cabozantinib in bladder cancer #asco22 | The Uromigos strives to provide balanced, scientific content related to care of patients with GU malignancies. Click the link below to listen to our podcasts. | Company / Organization | Media / News |
cm-9er | cabozantinib,nivolumab | exelixis,bms | gu | 1 | ['nivo', 'nivolumab', 'cabozantinib', 'gucsm', 'rcc,(-irccs),(-srcc),(-urcc)'] | 6/3/2022 18:10 | 1,530,000,000,000,000,000 | nivolumab/cabozantinib associated w/ greater proportion of deep objective responses for advanced #rcc #asco22 #ascodailynews #gucsm | Account of the American Society of Clinical Oncology & its affiliate the Association for Clinical Oncology. Assoc tweets labeled #ASCOAdvocacy. RTs ? endorse. | Company / Organization | Professional |
cm-9er | cabozantinib,nivolumab | exelixis,bms | gu | 1 | ['nivo', 'nivolumab', 'cabozantinib', 'renal,(-adrenal)'] | 6/3/2022 19:09 | 1,530,000,000,000,000,000 | #asco22 #nivolumabcabozantinib associated with greater proportion of deep objective responses for advanced #renalcellcarcinoma | null | Individual | HCP |
atlantis,COSMIC-021-3-4-5 | cabozantinib,atezolizumab | exelixis,roche | gu | 1 | ['bladder', 'cabozantinib'] | 6/3/2022 16:11 | 1,530,000,000,000,000,000 | maintenance cabozantinib after 1st line chemo not showing activity in 1st line bladder cancer #asco22. further evidence that vegf targeted therapy does not have significant activity in bladder cancer. the last single agent vegf randomised trial? | Interested in Urology Cancers, biomarkers and drug development. | Individual | HCP |
atlantis,COSMIC-021-3-4-5 | cabozantinib,atezolizumab | exelixis,roche | gu | 1 | ['atezolizumab', 'bladder', 'cabozantinib'] | 6/3/2022 17:22 | 1,530,000,000,000,000,000 | bladder cancer: what s the role for cabozantinib plus atezolizumab: maintenance?. no role in 1l/2l and for cabozantinib as monotherapy. i think. #bladdercancer #asco22 | Jefe de Servicio de Oncología Médica y Coordinador de ORT del Área Sanitaria de Lugo, A Mariña e Monforte de Lemos. Transdisciplinar y Transideológico. | Individual | HCP |
COSMIC-021-3-4-5 | cabozantinib,atezolizumab | exelixis,roche | gu | 1 | ['urothelial carcinoma', 'atezolizumab', 'cabozantinib', 'urothelial', 'cosmic-021'] | 6/3/2022 9:00 | 1,530,000,000,000,000,000 | findings from three groups of the cosmic-021 study show benefit of cabozantinib plus atezolizumab in certain patients with locally advanced or metastatic urothelial carcinoma. the findings will be presented today at 3:57 p.m. cst. #asco22 | City of Hope is a National Cancer Institute-designated comprehensive cancer center for cancer, diabetes and other life-threatening diseases. | Company / Organization | Hospital / Clinic |
COSMIC-021-3-4-5 | cabozantinib,atezolizumab | exelixis,roche | gu | 1 | ['urothelial carcinoma', 'atezolizumab', 'cabozantinib', 'urothelial', 'cosmic-021'] | 6/3/2022 9:09 | 1,530,000,000,000,000,000 | cabozantinib (c) in combination with atezolizumab (a) in urothelial carcinoma (uc): results from cohorts 3, 4, 5 of the cosmic-021 study #asco22 | #PsyOnc @CettroOncologia | Former Postdoc Fellow & Visiting Scholar @cityofhope | @IPOSPsychoOncol BOD 2021-2023 | #ASCO22 FCOI: https://t.co/wuOhYiJHBM | Individual | HCP |
COSMIC-021-3-4-5 | cabozantinib,atezolizumab | exelixis,roche | gu | 1 | ['blcsm', 'cabozantinib', 'urothelial'] | 6/3/2022 20:15 | 1,530,000,000,000,000,000 | dr. pal reported remarkable activity for combo atezo+cabozantinib in advanced urothelial ca: tumor regressions reported in over half pts (62-74%) including those who are cisplatin-eligible/ineligible and also in pts pretreated with ici #asco22 #blcsm | Medical oncologist - Developmental Therapeutics - NIH/NCI - opinions my own - retweet is not endorsement | Individual | HCP |
COSMIC-021-3-4-5 | cabozantinib,atezolizumab | exelixis,roche | gu | 1 | ['atezolizumab', '#gu ,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'cabozantinib', 'urothelial', 'gu ', 'cosmic-021', 'exelixis', 'exelixisinc'] | 6/3/2022 14:29 | 1,530,000,000,000,000,000 | reveals results from cohorts 3, 4, 5 of the cosmic-021 study. cabozantinib in combination with atezolizumab in #urothelialcarcinoma join at 3:57 pm in arie crown. #asco22 #gu #oncology | Creating Aha! Moments In Healthcare
IDEOlogy Health is leading the change in how healthcare professionals connect and stay up-to-date on the latest advancements | Company / Organization | Consulting / Analytics |
COSMIC-021-3-4-5 | cabozantinib,atezolizumab | exelixis,roche | gu | 1 | ['atezolizumab', 'cabozantinib', ' uc,(-ucsd),(-ucsf),'] | 6/3/2022 15:59 | 1,530,000,000,000,000,000 | cabozantinib in combination with atezolizumab demonstrated encouraging clinical activity in metastatic uc as first-line systemic therapy by #asco22 | Medical oncologist. Clinical researcher focused in GU tumors. Director Institute of Oncology. Associate Professor UCM. Hospital Clinico San Carlos Madrid, Spain | Individual | HCP |
COSMIC-021-3-4-5 | cabozantinib,atezolizumab | exelixis,roche | gu | 1 | ['urothelial'] | 6/3/2022 16:03 | 1,530,000,000,000,000,000 | great presentation by of the results of cabo-atezo in urothelial tumors. encouraging data. #asco22 | Medical Oncologist - Urologic Oncology. Hospital Universitario La Paz - IdiPAZ, Madrid | Individual | HCP |
COSMIC-021-3-4-5 | cabozantinib,atezolizumab | exelixis,roche | gu | 1 | ['urothelial carcinoma', 'atezolizumab', 'bladder', 'cabozantinib', 'urothelial'] | 6/3/2022 16:11 | 1,530,000,000,000,000,000 | nice talk from at #asco22 during the genitourinary cancer kidney and bladder session, concluding that cabozantinib plus atezolizumab demonstrated clinical activity in inop. locally-advanced/metastatic urothelial carcinoma | Independent and international experts in GenitoUrinary (GU) oncology. Part of https://t.co/QAbKORwRcf | Company / Organization | Professional |
COSMIC-021-3-4-5 | cabozantinib,atezolizumab | exelixis,roche | gu | 1 | ['atezolizumab', 'cabozantinib', 'urothelial'] | 6/3/2022 19:12 | 1,530,000,000,000,000,000 | #asco22 #cabozantinibatezolizumab active in cisplatin-eligible/ineligible, prior ici-exposed #urothelialcarcinoma | null | Individual | HCP |
COSMIC-021-3-4-5,LEAP | cabozantinib,atezolizumab | exelixis,roche | gu | 1 | ['atezolizumab', 'cabozantinib', 'urothelial'] | 6/3/2022 16:02 | 1,530,000,000,000,000,000 | failure of leap to meet primary endpoints colour the interpretation of cabozantinib + atezolizumab trial in urothelial cancer. is this different combination showing enough to study further? #asco2022 | An Australian oncologist with an interest in GU malignancies, phase 1 trials, cycling and having fun with the family | Individual | HCP |
COSMIC-021-7-20 | cabozantinib,atezolizumab | exelixis,roche | thoracic | 1 | ['sclc', 'nsclc', 'cabozantinib'] | 6/3/2022 14:33 | 1,530,000,000,000,000,000 | cabozantinib+atezo or cabozantinib alone in previously treated nsclc patients. again... "bof" or "meh". (sorry for wall street)
#asco22 | Head of pulmonology unit @pneumo_LS @CHUdeLyon
Professor of Pulmonology @UnivLyon1
Scientific head @URCOT_lyon & @IFCTlung
#liquidbiopsy~#screening~???? | Individual | HCP |
COSMIC-021-7-20 | cabozantinib,atezolizumab | exelixis,roche | thoracic | 1 | ['atezolizumab', 'cabozantinib'] | 6/3/2022 14:32 | 1,530,000,000,000,000,000 | #asco22 cabozantinib + atezolizumab (post io) showed rr 19% , dcr 80%, mdor 5.8m. cabozantinib alone with rr 6% and mdor 10.6m (but only n=2). mpfs 4.5m with combo and 3.4m mono. mos 13.8m with combo and 9.4m mono. | Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him | Individual | HCP |
COSMIC-021-7-20 | cabozantinib,atezolizumab | exelixis,roche | thoracic | 1 | ['atezolizumab', 'sclc', 'nsclc', 'cabozantinib', 'cosmic-021', 'exelixis', 'exelixisinc'] | 6/3/2022 12:14 | 1,530,000,000,000,000,000 | presents results from cohorts 7 and 20 of the cosmic-021 study: cabozantinib (c) plus atezolizumab (a) or c alone in patients with ansclc previously treated with an immune checkpoint inhibitor. today at 1 pm in hall d1 #asco22 | Creating Aha! Moments In Healthcare
IDEOlogy Health is leading the change in how healthcare professionals connect and stay up-to-date on the latest advancements | Company / Organization | Consulting / Analytics |
COSMIC-021-7-20 | cabozantinib,atezolizumab | exelixis,roche | thoracic | 1 | [] | 6/3/2022 14:32 | 1,530,000,000,000,000,000 | cabo+atz seems can overcome io resistance and has encouraging activity.#asco2022 | Professor, Head and Neck-Medical Oncologist, Neuro-Medical Oncologist, Thoracic-Medical Oncologist,Researcher,Immunotherapy, Statistics and Phase 1/2/3 studies | Individual | HCP |
COSMIC-021-7-20 | cabozantinib,atezolizumab | exelixis,roche | thoracic | 1 | ['lcsm,(-blcsm)', 'abate'] | 6/3/2022 14:35 | 1,530,000,000,000,000,000 | cabatezo or atecabo? great to see other trials underway for this combination. intriguing to see potential activity of atezo after failure of previous io. still much to learn! #asco22 #lcsm | Husband, father of 2, oncologist, marathoner, ultrarunner. Trains to inspire and works to push back limits of cancer treatment. | Individual | HCP |
COSMIC-021-7-20 | cabozantinib,atezolizumab | exelixis,roche | thoracic | 1 | ['lcsm,(-blcsm)', 'sclc', 'nsclc', 'biomarker'] | 6/3/2022 14:53 | 1,530,000,000,000,000,000 | promising data for cabo+atezo. no biomarker is available to determine who benefits most from anti-angiogenesis in #nsclc #asco22 #lcsm | #HemeOnc @LombardiCancer | @EmoryDeptofMed @GradyHealth @tulanemedicine alum | Interests #MedEd #clinicaltrials #disparities #lcsm ????|??mom | she/her/hers?? | Individual | HCP |
COSMIC-021-3-4-5 | sacituzumab govitecan,cabozantinib,atezolizumab | gilead sciences,exelixis,roche | gu | 1 | ['trodelvy'] | 6/3/2022 21:40 | 1,530,000,000,000,000,000 | cabo failed. ev & trodelvy better. | null | Individual | Blogger / Random / Other |
COSMIC-021-3-4-5 | sacituzumab govitecan,cabozantinib,atezolizumab | gilead sciences,exelixis,roche | gu | 1 | ['trodelvy'] | 6/3/2022 21:42 | 1,530,000,000,000,000,000 | cabo/tki failed again. ev/ trodelvy far better. | null | Individual | Blogger / Random / Other |
quilt-3.032 | n-803 | immunitybio | gu | 1 | ['anktiva', 'bladder', '$ibrx', 'immunitybio'] | 6/4/2022 7:42 | 1,530,000,000,000,000,000 | dr. kukreja previews bladder cancer abstracts presented at #asco22 $ibrx superagonist n-803 (anktiva) is mentioned as
"game changer for bladder #cancer patients" | #Commodities #Uranium #Biotech | Subscribe to my free blog, podcast & YT: https://t.co/gwiArtu8D6 | My #wikifolio fund trades on German Stock Exchange: https://t.co/EZPRC4lTCf | Individual | Finance / Investment |
quilt-3.032 | N-803 | immunitybio | gu | 1 | ['nmibc', 'mibc', 'pivotal', '$ibrx', 'immunitybio'] | 6/4/2022 10:41 | 1,530,000,000,000,000,000 | #asco22 coverage of "final clinical results of pivotal trial of il-15r fc superagonist n-803 with bcg in bcg-unresponsive cis and papillary nmibc" $ibrx #cancerresearch | #Commodities #Uranium #Biotech | Subscribe to my free blog, podcast & YT: https://t.co/gwiArtu8D6 | My #wikifolio fund trades on German Stock Exchange: https://t.co/EZPRC4lTCf | Individual | Finance / Investment |
LocoMMotion | teclistamab | janssen | multiple myeloma | 1 | ['mmsm'] | 6/4/2022 18:12 | 1,530,000,000,000,000,000 | theres a lot of talk about "top 5 or top 10" abstract lists at #asco2022 and a lot of hype. in this , i highlight 5 flawed myeloma studies. i mean no offense to the well intentioned investigators, but do this to encourage critical inquiry and debate. read on. #mmsm | Cancer doctor at @huntsmancancer with interest in myeloma, supportive care, end of life, cost-effective/evidence-based care and med-ed. No COI. Views own. | Individual | HCP |
kn-564 | pembrolizumab | merck | gu | 1 | [] | 6/4/2022 14:26 | 1,530,000,000,000,000,000 | m1 ned should show os benefit .. | Doing my part to help onc patients. + fintwit | Individual | HCP |
COSMIC-021-3-4-5 | cabozantinib,pembrolizumab,atezolizumab | merck,exelixis,roche | gu | 1 | ['atezolizumab', 'bladder', 'cabozantinib', 'pembrolizumab'] | 6/3/2022 16:05 | 1,530,000,000,000,000,000 | cabozantinib and atezolizumab showing response rates of 20-30% and os ~13 months in 1st line bladder cancer. this doesn t appear much greater than pembrolizumab alone from 361 or 52. in my opinion this probably shouldn t be explored further in 1st line disease. #asco22 | Interested in Urology Cancers, biomarkers and drug development. | Individual | HCP |
quilt-3.032,KN-057 | pembrolizumab,n-803 | merck,immunitybio | gu | 1 | [] | 6/3/2022 22:18 | 1,530,000,000,000,000,000 | additional data comparing n-803 vs pembro (kn-057) - karim chamie cr rate cis: 71% vs 41% cr rate cis, : 71% vs 29% cr rate cis/ht ta @ baseline: 81% vs 29% cr rate cis/t1 @ baseline: 67% vs 42% mdor of cr: 26.6 m vs 16.2 m rc rate: 15.8% vs 41.6% #asco22 | Uro Onc @GACancerCenter | Res PD & Ronald W. Lewis MD Chair of Uro Educ @mcg_urology | Digital Media Ed @EUplatinum | #mentalhealth research | @urotoday | Individual | HCP |
quilt-3.032,KN-057 | pembrolizumab,n-803 | merck,immunitybio | gu | 1 | ['bladder', 'pembrolizumab'] | 6/3/2022 18:26 | 1,530,000,000,000,000,000 | data close to those observed with #pembrolizumab which seem that immunomodulation is the way to avoid surgery in these high-risk tumors american society of clinical oncology (asco) #asco2022 #day1 #bladdercancer | Medical Oncologist, Urologic Oncology. Running Addict.@CHRU_Brest | Individual | HCP |
Not Tagged | dcvax-l | northwest biotherapeutics | Not Tagged | 1 | [' vision', 'dcvax', 'nwbo'] | 6/6/2022 20:05 | 1,530,000,000,000,000,000 | via we now appreciate l. powers delivery of her vision for #nwbo and #dcvax @ #asco22. #flaskworks #crl #sawston video clip is from asco 2018 | Critical thinker, obsessive, explorer | Individual | HCP |
everest | everolimus | Not Tagged | gu,other | 1 | ['everest'] | 6/3/2022 14:59 | 1,530,000,000,000,000,000 | so exciting to see the results of #everest presented at #asco22. we were the highest enrolling site at . outcome is thought provoking. will not change soc but intriguing to think that some subsets could benefit - could mtor pathway altered pts drive benefit too? | @cityofhope & @cityofhopeoc prof w focus on #kidneycancer, #prostatecancer, #bladdercancer & 90s rock. RTs not endorsements. COI: https://t.co/L7ihnCjLz5 | Individual | HCP |
everest | everolimus | Not Tagged | gu,other | 1 | ['kcsm,(-skcsm)', 'everest'] | 6/3/2022 15:08 | 1,530,000,000,000,000,000 | everest trial. a new negative adjuvant trial in #kcsm. #asco22 waiting overall survival for pembroluzimab! | Oncólogo Clínico staff @IAF_Fleming. Miembro @SelnetH2020 @aaoncoclinica. Interesado en #GUcsm. #clinicaltrials. #Immunotherapy #PrecisionMedicine #oncoalert | Individual | HCP |
everest | everolimus | Not Tagged | gu,other | 1 | ['everest', 'renal,(-adrenal)'] | 6/3/2022 14:59 | 1,530,000,000,000,000,000 | another negative study for os in renal cancer adjuvant therapy
#everest #asco22 | Medical oncologist. Lung and genitourinary cancer.
#lcsm #pcsm #kcsm | Individual | HCP |
everest | everolimus | Not Tagged | gu,other | 1 | ['everest', 'rcc,(-irccs),(-srcc),(-urcc)', 'knight'] | 6/3/2022 14:49 | 1,530,000,000,000,000,000 | #asco22 dr chris ryan presenting results of everest ph3 results for #rcc | Physician-scientist at OHSU specializing in sarcomas, especially bone sarcomas and sarcomas in adolescents & young adults (AYAs). #OHSUSarcoma | Individual | HCP |
everest | everolimus | Not Tagged | gu | 1 | ['gu '] | 6/3/2022 15:44 | 1,530,000,000,000,000,000 | agree. this was considered #1 abstract in the gu top list for this asco. we definitely need higher bars to consider what is to mover forward | Associate Oncologist Sirio Libanes Hospital, Sao Paulo
Head of Clinical Research in Oncology, Sirio Libanes Hospital
Scientific Director LACOG, Genitourinary | Individual | HCP |
everest | everolimus | Not Tagged | gu | 1 | [] | 6/3/2022 15:54 | 1,530,000,000,000,000,000 | statistically negative. clinically no meaningful benefit. suspect this surprised no one. | null | Individual | HCP |
everest | everolimus | Not Tagged | gu | 1 | [] | 6/3/2022 19:27 | 1,530,000,000,000,000,000 | 'nominal significance level was narrowly missed', i heard for the first time in my life. lawyers seem to expand its circular language to oncology. | Un ácrata muy atemperado por el NIF. Un cabreado por la absurda exigencia de morirse y no ver más inventos. | Individual | HCP |
everest | everolimus | Not Tagged | gu | 1 | [] | 6/4/2022 9:10 | 1,530,000,000,000,000,000 | folks used to word that differently ie. the adjuvant stage 2 colon cancer data from 20+ years ago. benefit was referred to as a "trend that didn't quite reach statistical significance." | null | Individual | HCP |
everest | everolimus | Not Tagged | gu,other | 1 | ['everest', 'gu '] | 6/3/2022 14:56 | 1,530,000,000,000,000,000 | gu abstract #asco2022 moderated by dr. eric singer and dr. buphati. dr. ryan presenting everest results. | medical oncologist, hematologist, palliative care MD and educator. views and ramblings are my own. | Individual | HCP |
everest | everolimus | Not Tagged | gu,other | 1 | ['everest'] | 6/3/2022 14:57 | 1,530,000,000,000,000,000 | watching moderate dr. ryan during everest discussion from afar! great virtual platform #asco22 | Interim Chair/Executive Director @GUUrology Husband to @tarablelawyer??@Patriots @Arsenal @NotreDame @NHLBruins Superstar at the cracker factory VIEWS MINE | Individual | HCP |
Not Tagged | Not Tagged | Not Tagged | other | 1 | ['bcsm', ' vision'] | 6/6/2022 16:11 | 1,530,000,000,000,000,000 | i once made a vision board with this phenomenal advocate and now we both have seen so many things materialize. giving of ourselves on behalf of others (not so humble brag) #bcsm #asco2022 | Patient Advocate, Harvard Cancer Center, Komen AIS, YSC RISE, MA State Leader Tweets mine | Individual | Advocacy / Charity |
vision | 177lu-psma-617 | novartis | gu | 1 | [] | 6/5/2022 8:36 | 1,530,000,000,000,000,000 | #asco22 a #vision substudy: association between suvmean and survival outcomes + absence of psma+ in liver and bone associated with improved rpfs and os! | Director, @danaFarber_GU & International Strategic Initiatives @DanaFarber. Kohlberg Prof. of Medicine @Harvardmed. @PanMass rider. #SoccerIsLife. Views Mine. | Individual | HCP |
vision | 177lu-psma-617 | novartis | gu | 1 | ['crpc', '68g'] | 6/5/2022 14:30 | 1,530,000,000,000,000,000 | [68ga]ga-psma-11 pet baseline imaging as a prognostic tool for clinical outcomes to [177lu]lu-psma-617 in patients with #mcrpc: a #vision substudy. presentation by . #asco22 written coverage by > | Largest global online community of #urological medical professionals & patients. #AUA22 #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology | Company / Organization | Professional |
vision | 177lu-psma-617 | novartis | gu | 1 | ['crpc', 'prostate'] | 6/5/2022 9:11 | 1,530,000,000,000,000,000 | psma pet/tc as prognostic factor in mcrpc treated with lu-psma #asco22 #prostatecancer | Jefe de Servicio de Oncología Médica y Coordinador de ORT del Área Sanitaria de Lugo, A Mariña e Monforte de Lemos. Transdisciplinar y Transideológico. | Individual | HCP |
vision | 177lu-psma-617 | novartis | gu | 1 | ['crpc'] | 6/4/2022 15:00 | 1,530,000,000,000,000,000 | [177lu]lu-psma-617 in psma-positive #mcrpc: prior and concomitant treatment subgroup analyses of the #vision trial. don't miss, #asco22 presentation by nitin vaishampayan, md jun 5th > 9:12 9:24 am edt | Largest global online community of #urological medical professionals & patients. #AUA22 #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology | Company / Organization | Professional |
vision | 177lu-psma-617 | novartis | gu | 1 | [' vision'] | 6/5/2022 8:28 | 1,530,000,000,000,000,000 | excellent presentation on subgroup analysis by prior and concurrent therapy from vision. consistent benefit independent of prior or concurrent therapy. | GU medical oncologist @UCSanDiego, mom, wife, avid runner. Kidney and prostate cancer research. Tweets are my own and not medical advice. | Individual | HCP |
vision | 177lu-psma-617 | novartis | gu | 1 | ['prime'] | 6/5/2022 8:30 | 1,530,000,000,000,000,000 | giving us a primer on suvmean, suvmax & volume on psma pet/ct. wonderful to see medical oncology embracing quantitative pet. #asco22 | Working together to improve patient outcomes with personalised medicine: PET/CT, theranostics. Nuclear Medicine Physician ?? Prof ???? | Individual | HCP |
vision | 177lu-psma-617 | novartis | gu | 1 | ['prostate'] | 6/5/2022 12:07 | 1,530,000,000,000,000,000 | i found this result a little perplexing- in context of absence of psma + in bone portending improved os in prostate cancer . | GU Medical Oncologist. Clinical investigator. Cleveland Clinic alum. Views my own. | Individual | HCP |
vision | 177lu-psma-617 | novartis | gu | 1 | ['pcsm', 'crpc', 'prostate'] | 6/5/2022 18:11 | 1,530,000,000,000,000,000 | psma-pet criteria identified to optimize mcrpc patient selection for 177lu-psma-617 #asco22 #urology #urologist #pcsm #prostatecancer | Expert clinical analysis. Practice advice. Policy perspectives. | Company / Organization | Publication / Journal |
vision | 177lu-psma-617 | novartis | gu | 1 | ['prostate', 'novartis'] | 6/6/2022 15:43 | 1,530,000,000,000,000,000 | at #asco22, researchers shared efforts to better define which prostate cancer patients benefit most from novartis' and how to optimize selection w/ psma pet imaging. but the discussions came against the backdrop of real-world access issues | Health & science journalist ???Biopharma reporter @PrecOncNews @GenomeWeb?Past: @ASCO, @ColumbiaJourn?I cover cancer treatment??, genomics??, + sometimes ??s | Individual | Media / News |
enzamet | enzalutamide | pfizer,astellas | gu | 1 | [] | 6/5/2022 9:18 | 1,530,000,000,000,000,000 | enzalutamide added to testosterone suppression for mhspc provided clinically meaningful improvements in os for the combined study cohort; most apparent for low volume mhspc in those for whom docetaxel was not deemed necessary #asco22 | Medical oncologist. Lung and genitourinary cancer.
#lcsm #pcsm #kcsm | Individual | HCP |
CM-214 | sunitinib,nivolumab,ipilimumab | pfizer,BMS | GU | 1 | ['sunitinib'] | 6/3/2022 15:57 | 1,530,000,000,000,000,000 | a little surprising in one sense: i ve always thought that a little toxicity for sunitinib means you re more likely to have a therapeutic drug concentration, compared to those with no toxicity. hrqol balances treatment toxicity against fewer symptoms if cancer responding. #asco22 | Professor of medicine | medical oncologist | head EH clinical school | Chair, ANZUP | husband, father, grandfather, blessed | want to make a positive difference | Individual | HCP |
Not Tagged | obinutuzumab,lenalidomide | roche | lymphoma | 1 | ['lymsm', 'award', 'dlbcl', 'obinutuzumab'] | 6/4/2022 11:05 | 1,530,000,000,000,000,000 | excellent work by presenting our trial of obinutuzumab + lenalidomide with chop for patients with new dlbcl, supported by a award! #asco22 #lymsm | Director of Clinical Research, Section Chief of Aggressive Lymphomas @MDAndersonNews, @ASCO Board member & Govt Relations Committee Chair-elect, Opinions mine | Individual | HCP |
POLARIX | Polatuzumab,Rituximab,Doxorubicin,Prednisone | roche,abbvie,biogen | lymphoma | 1 | ['lymsm', 'dlbcl'] | 6/4/2022 9:16 | 1,530,000,000,000,000,000 | a thoughtful, independent cost-effectiveness analysis that will inform clinicians (and htas!) deciding about pola-r-chp in dlbcl & should be commended. hopefully time confirms positive findings #lymsm #asco22 | haematology registrar | evidence-based medicine | MPH @Harvard | health policy @PORTAL_research | physiology | musician | writer | @_futurethinkers cofounder | Individual | Research / Science |
POLARIX | Polatuzumab,Etoposide,Rituximab,Doxorubicin,Prednisone | roche,abbvie,biogen | lymphoma | 1 | ['lymsm', 'dlbcl'] | 6/3/2022 17:35 | 1,530,000,000,000,000,000 | do we need to do another pola-epchr, maybe pola-chpr is enough in this high risk population. hope to see biology to justify the the regimen in dlbcl #lymsm #asco22 | A hematologist @MoffittNews with interest in #lymsm. Tweets are not endorsements, and not medical advice. | Individual | HCP |
POLARIX | Polatuzumab,Rituximab,Doxorubicin,Prednisone | roche,abbvie,biogen | lymphoma | 1 | ['lymsm', 'dlbcl'] | 6/3/2022 17:55 | 1,530,000,000,000,000,000 | polachpr does not increase peripheral neuropathy in dlbcl #lymsm in comparison to rchop #asco22 | A hematologist @MoffittNews with interest in #lymsm. Tweets are not endorsements, and not medical advice. | Individual | HCP |
COSMIC-021-3-4-5 | atezolizumab,cabozantinib | roche,exelixis | gu | 1 | ['blcsm', 'cabozantinib', 'atezo', 'urothelial'] | 6/4/2022 8:23 | 1,530,000,000,000,000,000 | atezolizumab plus cabozantinib elicits clinical activity in advanced urothelial cancer #asco22 #blcsm | Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management. | Company / Organization | Publication / Journal |
tapur | cobimetinib,vemurafenib | roche,exelixis | other | 1 | [' vision', 'tapur'] | 6/6/2022 14:44 | 1,530,000,000,000,000,000 | thankful for your visionary leadership and for the amazing #tapur team making #clinicaltrial participation an accessible option for #precisionmedicine interventions! #stage4cancer | Medical Director Clinical Operations, Cancer Survivorship Program; Breast Oncologist @SylvesterCancer, AD of Community Outreach. #WomenInMedicine tweets=my own | Individual | HCP |
determination | Lenalidomide,bortezomib,dexamethasone | Takeda,Acrotech | gi,multiple myeloma | 1 | ['mmsm', 'triplet'] | 6/5/2022 7:10 | 1,530,000,000,000,000,000 | triplet therapy, transplantation, and maintenance until progression in myeloma | nejm #asco22 looking forward to the plenary talk and discussion. high dose melphalan wins again to no one s surprise. #mmsm | Chief of Myeloma @MSKCancerCenter | Chair @ALLIANCE_org #mmsm Comm. |Physician ? Provider| @ASH_hematology @ASTCT @ASCO |married to @ZainabShd | #BMTsm #CARTsm | Individual | HCP |
not tagged | not tagged | 2seventy bio | not tagged | 1 | ['$tsvt', '2seventy bio'] | 6/6/2022 5:37 | 1,530,000,000,000,000,000 | $tsvt #2seventy bio inc ... asco 2022 roundup for covered companies (part 1): [...] #equity #stocks | @ResearchPool helps the buy-side, sell-side and corporates discover research quickly, streamline workflows and broaden distribution. #valuingknowledge | Company / Organization | Finance / Investment |
karmma | idecabtagene vicleucel | 2seventy bio,bms | multiple myeloma | 1 | ['car t', 'multiplemyeloma', 'idecabtagene vicleucel'] | 6/4/2022 17:15 | 1,530,000,000,000,000,000 | today at #asco22, doris hansen shares real-world experience on idecabtagene vicleucel car t-cell therapy for relapsed/refractory #multiplemyeloma. | The official account of Moffitt Cancer Center. Our mission: to contribute to the prevention and cure of cancer. For news and stories visit https://t.co/XaP6iv4q19. | Company / Organization | Hospital / Clinic |
Not Tagged | idecabtagene vicleucel | 2seventy bio,bms | multiple myeloma | 1 | ['abecma', 'mmsm'] | 6/4/2022 20:06 | 1,530,000,000,000,000,000 | do #myeloma patients have to meet the clinical trial criteria to receive abecma as standard of care and still have it be effective? not really. #mmsm #asco22 #peerview | Supporting, educating and connecting #myeloma patients and their loved ones while actively seeking a cure. | Company / Organization | Advocacy / Charity |
karmma | bb2121,idecabtagene vicleucel | 2seventy bio,bms | multiple myeloma | 1 | ['car t', 'abecma', 'karmma', 'bmsnews', 'bms'] | 6/4/2022 14:52 | 1,530,000,000,000,000,000 | real world experience of #abecma from u.s. myeloma car t consortium at 2022
safety efficacy similar to karmma despite many ineligible for the trial. proud to be a part of this collaborative effort. | Assistant Professor Hematology/BMT @Muschollings Plasma cell disorders/ BMT/Cellular Therapy. Opinions are my own and not employer’s | Individual | HCP |
Not Tagged | mrx0518,avelumab | 4d pharma,merck,pfizer | Not Tagged | 1 | ['mrx0518', 'bavencio', 'avelumab'] | 6/3/2022 5:07 | 1,530,000,000,000,000,000 | #dddd $lbps #mrx0518 #asco22 #bavencio #avelumab #oncology there's a poster presentation tomorrow at for the phase ii clinical trial of mrx0518 in combination with bavencio (avelumab). | 10n | Individual | Blogger / Random / Other |
basecamp-1 | Leukapheresis | A2 Biotherapeutics | other | 1 | ['solid tumor', 'cart,(-cartitude)'] | 6/5/2022 8:05 | 1,530,000,000,000,000,000 | the basecamp-1 study is currently enrolling participants to explore the feasibility of manufacturing a novel #cartcell therapy that targets a key tumor escape mechanism in patients with solid tumors. #asco22 | CGTLive™ delivers quality and relevant information to healthcare professionals on cell, gene, regenerative, and engineered medicines to ultimately improve care. | Company / Organization | Healthcare |
basecamp-1 | leukapheresis | a2 biotherapeutics | other,thoracic,gi | 1 | ['basecamp-1', 'car t'] | 6/6/2022 7:04 | 1,530,000,000,000,000,000 | the basecamp-1 study is currently enrolling participants to explore the feasibility of manufacturing a novel car t-cell therapy with a target antigen activator and a hla loh-based blocker. #asco22 | CGTLive™ delivers quality and relevant information to healthcare professionals on cell, gene, regenerative, and engineered medicines to ultimately improve care. | Company / Organization | Healthcare |
Not Tagged | Not Tagged | aadi biosciences | Not Tagged | 1 | ['aadibio', 'aadi bioscience'] | 6/4/2022 12:45 | 1,530,000,000,000,000,000 | join us at #asco2022 june 3-7 in chicago. we look forward to seeing you at our booths #22113 and #23112. learn more here: | Aadi Bio is a commercial-stage #precisiononcology company striving to unleash the potential of mTOR inhibition via precision medicine & nanoparticle technology. | Company / Organization | Pharma / Biotech |
refine | navitoclax,ruxolitinib | abbvie | myeloid | 1 | ['refine ', 'mpnsm', '#mpn', 'leusm', 'navitoclax'] | 6/4/2022 14:10 | 1,530,000,000,000,000,000 | #asco22 #leusm #mpnsm menghrajani: navitoclax + rux shown to have promise in ph2 study in those with pd or poor resp to jaki. here, preliminary data from frontline navitoclax + rux ph2 refine study show good spleen size redxn responses; thrombocytopenia an issue (47% gr3+). | Assoc Professor, UCSF hematology/BMT. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG) | Individual | HCP |
Not Tagged | Not Tagged | abbvie | myeloid | 1 | ['leukemia', 'aml,(-streamline),(-seamless),(-kamloops)', 'myeloid', 'abbvie'] | 6/3/2022 8:00 | 1,530,000,000,000,000,000 | welcoming oncologists and researchers from across the globe to our neighborhood: chicago is home to our global hq and #asco22. join us tomorrow where we ll be highlighting data on untreated acute myeloid leukemia (#aml). view more at : | AbbVie’s Twitter feed featuring news and updates from our U.S. business. Intended for U.S. residents only. Review our guidelines here: https://t.co/CMljIbzTPP | Company / Organization | Pharma / Biotech |
Not Tagged | Not Tagged | abbvie | Not Tagged | 1 | ['abbvie'] | 6/4/2022 10:00 | 1,530,000,000,000,000,000 | scientists new discoveries launched a renaissance in #bloodcancer #treatment. see what it means for patients: #asco22 | AbbVie's global handle featuring biopharmaceutical news & updates managed by our corp digital team. Review our guidelines: https://t.co/RJsgPRX3Cb… | Company / Organization | Pharma / Biotech |
Not Tagged | Not Tagged | abbvie | Not Tagged | 1 | ['party', 'abbvie'] | 6/5/2022 16:00 | 1,530,000,000,000,000,000 | j&j and abbvie popped the cork on some preliminary data at #asco22 showing imbruvica kept a rare and aggressive form of cancer at bay in combination with two other drugs for more than six years. but will overall survival data crash the party? | The biopharma world is here. Get the industry’s most comprehensive daily news report at https://t.co/rXFyNyZcJs | Bot / Aggregator | Media / News |
LUMINOSITY | telisotuzumab | abbvie | thoracic | 1 | ['sclc', 'lcsm,(-blcsm)', 'telisotuzumab', ' vision', 'nsclc'] | 6/6/2022 13:54 | 1,530,000,000,000,000,000 | #asco22 update on telisotuzumab vedotin (teliso-v), a met-idc in met ihc+ nsclc. toxicities include edema (common with met inhibitors, often dose-limiting in my experience) and here, blurry vision and keratitis (low grade). #lcsm | Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him | Individual | HCP |
Not Tagged | Not Tagged | abbvie | Not Tagged | 1 | ['$abbv'] | 6/3/2022 7:54 | 1,530,000,000,000,000,000 | $abbv 10-jun-22 straddle implies a 3.1% move. jun 6 2022 american society of clinical oncology (asco) annual meeting | Marker Chameleon- Instant updates UNUSUAL OPTION VOLUME | IMPLIED VOLATILITY | PRICE ACTION | Bot / Aggregator | Finance / Investment |
Not Tagged | Not Tagged | abbvie | myeloid | 1 | ['#myelof', 'abbvie'] | 6/3/2022 14:00 | 1,530,000,000,000,000,000 | tomorrow we ll be sharing data from a study in #myelofibrosis (mf), as part of our larger oncology portfolio at #asco22. view more at : | AbbVie’s Twitter feed featuring news and updates from our U.S. business. Intended for U.S. residents only. Review our guidelines here: https://t.co/CMljIbzTPP | Company / Organization | Pharma / Biotech |
Luminosity | telisotuzumab | abbvie | thoracic | 1 | ['lcsm,(-blcsm)', ' vision'] | 6/6/2022 14:02 | 1,530,000,000,000,000,000 | luminosity- teliso-v, an adc targeting met with cytotoxic microtubular inhibitor payload--> encouraging results for non-squamous, wild-type subset, especially for high met expression... concerning aes- neuropathy, vision changes, keratitis and pneumonitis #asco22 #lcsm | Assistant Prof | Thoracic Oncology & Phase-I @karmanoscancer | Previously @MayoCancerCare @gundersenhealth @JeffHealthAb @bpkihsofficial | Views/Tweets my own | Individual | HCP |
Not Tagged | Not Tagged | abbvie | Not Tagged | 1 | ['import', 'abbvie', 'evelo'] | 6/3/2022 15:00 | 1,530,000,000,000,000,000 | today s #asco22 kickoff is exciting whether you re in chicago or following virtually! our global development lead, james dean, m.d., ph.d., reflects on the importance of these meetings to advance the treatment landscape for people with #bloodcancer. | Official Twitter Site for Pharmacyclics, an AbbVie Company.
Review our community guidelines here: https://t.co/yF1pVcUTKO | Company / Organization | Pharma / Biotech |
Not Tagged | telisotuzumab | abbvie | Not Tagged | 1 | [' vision'] | 6/6/2022 13:36 | 1,530,000,000,000,000,000 | #asco22 teliso-v adds different types of toxicities including neuropathy and vision changes and some familar met toxicities like edema. | Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him | Individual | HCP |
Not Tagged | Not Tagged | abbvie | myeloid | 1 | ['#myelof', 'abbvie'] | 6/5/2022 10:00 | 1,530,000,000,000,000,000 | preliminary results from a phase 2 trial in #myelofibrosis (mf) will be shared at #asco22. mf is a rare blood cancer that develops when a genetic mutation occurs in blood stem cells. view more at : | AbbVie’s Twitter feed featuring news and updates from our U.S. business. Intended for U.S. residents only. Review our guidelines here: https://t.co/CMljIbzTPP | Company / Organization | Pharma / Biotech |
Not Tagged | Not Tagged | abbvie | thoracic | 1 | ['nsclc', 'lung', 'sclc', 'abbvie'] | 6/5/2022 10:00 | 1,530,000,000,000,000,000 | at #asco22, we re sharing early data about our research in c-met overexpressing advanced non-small cell lung cancer (#nsclc). view more at : | AbbVie’s Twitter feed featuring news and updates from our U.S. business. Intended for U.S. residents only. Review our guidelines here: https://t.co/CMljIbzTPP | Company / Organization | Pharma / Biotech |
End of preview. Expand
in Dataset Viewer.
No dataset card yet
New: Create and edit this dataset card directly on the website!
Contribute a Dataset Card- Downloads last month
- 0